Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Accumulated Depreciation & Amortization (2016 - 2026)

Anika Therapeutics has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $52.8 million for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 10.72% to $52.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $52.8 million through Mar 2026, up 10.72% year-over-year, with the annual reading at $51.4 million for FY2025, 11.11% up from the prior year.
  • Accumulated Depreciation & Amortization was $52.8 million for Q1 2026 at Anika Therapeutics, up from $51.4 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $52.8 million in Q1 2026 and troughed at $44.0 million in Q4 2023.
  • The 5-year median for Accumulated Depreciation & Amortization is $47.6 million (2025), against an average of $48.4 million.
  • Year-over-year, Accumulated Depreciation & Amortization rose 16.67% in 2022 and then dropped 4.75% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $46.2 million in 2022, then fell by 4.75% to $44.0 million in 2023, then rose by 5.22% to $46.3 million in 2024, then increased by 11.11% to $51.4 million in 2025, then rose by 2.58% to $52.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Accumulated Depreciation & Amortization are $52.8 million (Q1 2026), $51.4 million (Q4 2025), and $50.6 million (Q2 2025).